YORBA LINDA, Calif. (PRWEB) October 26, 2017
Alzheimer’s disease (AD) affects more than 55 million people worldwide and is expected to double every 20 years in the absence of disease-modifying drugs. Future therapeutic strategies aimed at limiting neurodegeneration require methods to diagnose the disease in preclinical patients. Several blood-based tests have been explored to detect AD however, evidence is required to determine whether blood sampling is an appropriate specimen to diagnose brain diseases.
The Ion Torrent Ion S5 and Ion Chef system was used to perform small RNA deep sequencing of the brain and serum exosome samples. Brain derived exosomes (BDEs) were found to contain a unique profile of small RNA, including miRNA, compared to whole tissue samples. Furthermore, all 16 serum biomarkers, identified in the previous study, were detected in BDEs including a panel of BDE specific miRNA that target genes involved in AD pathology.
This work has identified a highly specific panel of miRNA that is both present in the brain and blood of AD patient samples. In the future, the miRNA candidates could be used to develop a blood-based diagnostic test highly relevant to a brain disease, equivalent to non-invasive brain biopsy. Furthermore, this biomarker discovery pipeline could be used to identify exosomal miRNA biomarkers for other diseases and conditions.
The team at Thermo Fisher Scientific Ion Torrent has arranged for Dr. Lesley Cheng, a postdoctoral
researcher at the College of Science, Health and Engineering in La Trobe University’s School of Molecular Sciences to present this webinar.
After earning her doctorate from Monash University, Australia, Cheng undertook a position in Research and Development at the American Hospital Dubai, developing diagnostic tests to screen neonatal babies for genetic disorders. In 2015, she moved to the La Trobe Institute for Molecular Science, La Trobe University. Currently, her major focus is to develop a minimally invasive blood test for the early detection and monitoring of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Prion disease.
LabRoots will host the webinar November 14, 2017 at 12 noon PST, 03:00pm EST. To read more about this event, or learn about the continuing education credits offered, and to register for free, click here.
For Research Only. Not for use in diagnostic procedures
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit http://www.thermofisher.com.
LabRoots is the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.